Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS. [electronic resource]
Producer: 20170509Description: 117-23 p. digitalISSN:- 1873-264X
- Antineoplastic Agents -- analysis
- Area Under Curve
- Calibration
- Chromatography, Liquid -- methods
- Chromatography, Reverse-Phase -- methods
- Drug Stability
- Drug Storage
- Half-Life
- Humans
- Imidazoles -- analysis
- Linear Models
- Oxazepines -- analysis
- Phosphoinositide-3 Kinase Inhibitors
- Reproducibility of Results
- Solid Phase Extraction -- methods
- Tandem Mass Spectrometry -- methods
- Temperature
- Time Factors
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Validation Study
There are no comments on this title.
Log in to your account to post a comment.